Generic Fenoglide Availability

Fenoglide is a brand name of fenofibrate, approved by the FDA in the following formulation(s):

FENOGLIDE (fenofibrate - tablet;oral)

  • Manufacturer: SANTARUS INC
    Approval date: August 10, 2007
    Strength(s): 40MG, 120MG [RLD]

Has a generic version of Fenoglide been approved?

No. There is currently no therapeutically equivalent version of Fenoglide available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fenoglide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Solid dosage form comprising a fibrate
    Patent 7,658,944
    Issued: February 9, 2010
    Inventor(s): Holm; Per & Norling; Tomas
    Assignee(s): LifeCycle Pharma A/S
    The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
    Patent expiration dates:
    • December 9, 2024
      ✓ 
      Drug product
  • Solid dosage form comprising a fibrate
    Patent 8,124,125
    Issued: February 28, 2012
    Inventor(s): Holm; Per & Norling; Tomas
    Assignee(s): Veloxis Pharmaceuticals A/S
    The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
    Patent expiration dates:
    • October 1, 2024
      ✓ 
      Patent use: FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
      ✓ 
      Drug product
  • Solid dosage form comprising a fibrate
    Patent 8,481,078
    Issued: July 9, 2013
    Assignee(s): Veloxis Pharmaceuticals A/S
    The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
    Patent expiration dates:
    • October 1, 2024
      ✓ 
      Patent use: USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)